PMC:7200337 / 53172-54099
Annnotations
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32505227-32259480-46575357 | 921-925 | 32259480 | denotes | 2020 |
| T18004 | 921-925 | 32259480 | denotes | 2020 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T531 | 381-389 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
| T532 | 432-446 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
| T533 | 726-734 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T340 | 75-83 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T341 | 138-146 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T342 | 318-321 | Disease | denotes | ADE | http://purl.obolibrary.org/obo/MONDO_0019383 |
| T343 | 471-474 | Disease | denotes | ADE | http://purl.obolibrary.org/obo/MONDO_0019383 |
| T344 | 496-504 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T345 | 648-656 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T346 | 659-668 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T661 | 476-479 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T662 | 825-827 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T89931 | 757-764 | Chemical | denotes | antigen | http://purl.obolibrary.org/obo/CHEBI_59132 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1735 | 695-697 | Gene | denotes | to | Gene:6999 |
| 1736 | 609-611 | Gene | denotes | to | Gene:6999 |
| 1737 | 585-587 | Gene | denotes | to | Gene:6999 |
| 1738 | 209-211 | Gene | denotes | to | Gene:6999 |
| 1739 | 97-99 | Gene | denotes | to | Gene:6999 |
| 1740 | 75-85 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 1741 | 339-342 | Species | denotes | CoV | Tax:11118 |
| 1742 | 505-513 | Species | denotes | patients | Tax:9606 |
| 1743 | 138-146 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1744 | 496-504 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1745 | 648-668 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T291 | 0-147 | Sentence | denotes | As of now, there is no evidence that naturally developed antibodies toward SARS-CoV-2 contribute to the pathological features observed in COVID-19. |
| T292 | 148-274 | Sentence | denotes | However, this possibility should be considered when it comes to experimental design and development of therapeutic strategies. |
| T293 | 275-409 | Sentence | denotes | Importantly, in all of the descriptions of ADE as it relates to CoV, the FcR was necessary to trigger the antibody-mediated pathology. |
| T294 | 410-669 | Sentence | denotes | High-dose intravenous immunoglobulin (IVIg), which may blunt ADE, has been trialed in COVID-19 patients (Cao et al., 2020b, Shao et al., 2020), but further studies are needed to determine the extent to which IVIg is safe or beneficial in SARS-CoV-2 infection. |
| T295 | 670-927 | Sentence | denotes | Vaccine trials will need to consider the possibility of antibody-driven pathology upon antigen rechallenge; strategies using F(ab) fragments or engineered Fc monoclonal antibodies may prove particularly beneficial in this setting (Amanat and Krammer, 2020). |